171 related articles for article (PubMed ID: 37493536)
21. Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice.
Feng D; Zhang H; Jiang X; Zou J; Li Q; Mai H; Su D; Ling W; Feng X
Environ Pollut; 2020 Oct; 265(Pt A):114880. PubMed ID: 32540565
[TBL] [Abstract][Full Text] [Related]
22. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
[TBL] [Abstract][Full Text] [Related]
23. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome.
Sung CM; Lin YF; Chen KF; Ke HM; Huang HY; Gong YN; Tsai WS; You JF; Lu MJ; Cheng HT; Lin CY; Kuo CJ; Tsai IJ; Hsieh SY
Cell Mol Gastroenterol Hepatol; 2019; 8(2):301-318.e2. PubMed ID: 31004827
[TBL] [Abstract][Full Text] [Related]
24. Exploratory investigation on nitro- and phospho-proteome cerebellum changes in hyperammonemia and hepatic encephalopathy rat models.
Brunelli L; Campagna R; Airoldi L; Cauli O; Llansola M; Boix J; Felipo V; Pastorelli R
Metab Brain Dis; 2012 Mar; 27(1):37-49. PubMed ID: 22083566
[TBL] [Abstract][Full Text] [Related]
25. The role of microbiota in hepatic encephalopathy.
Bajaj JS
Gut Microbes; 2014; 5(3):397-403. PubMed ID: 24690956
[TBL] [Abstract][Full Text] [Related]
26. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
Kristiansen RG; Rose CF; Ytrebø LM
Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
[TBL] [Abstract][Full Text] [Related]
27. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiota: its role in hepatic encephalopathy.
Rai R; Saraswat VA; Dhiman RK
J Clin Exp Hepatol; 2015 Mar; 5(Suppl 1):S29-36. PubMed ID: 26041954
[TBL] [Abstract][Full Text] [Related]
29. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
Stecher B
Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
[TBL] [Abstract][Full Text] [Related]
30. Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin.
Tamaoki S; Suzuki H; Okada M; Fukui N; Isobe M; Saito T
Eur J Pharmacol; 2016 May; 779():168-76. PubMed ID: 26980242
[TBL] [Abstract][Full Text] [Related]
31. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
Jalan R; Wright G; Davies NA; Hodges SJ
Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
[TBL] [Abstract][Full Text] [Related]
32. Neuropsychiatric Ramifications of COVID-19: Short-Chain Fatty Acid Deficiency and Disturbance of Microbiota-Gut-Brain Axis Signaling.
Sajdel-Sulkowska EM
Biomed Res Int; 2021; 2021():7880448. PubMed ID: 34651049
[TBL] [Abstract][Full Text] [Related]
33. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
Bajaj JS; Betrapally NS; Hylemon PB; Heuman DM; Daita K; White MB; Unser A; Thacker LR; Sanyal AJ; Kang DJ; Sikaroodi M; Gillevet PM
Hepatology; 2015 Oct; 62(4):1260-71. PubMed ID: 25820757
[TBL] [Abstract][Full Text] [Related]
34. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia.
Jamshidzadeh A; Heidari R; Abasvali M; Zarei M; Ommati MM; Abdoli N; Khodaei F; Yeganeh Y; Jafari F; Zarei A; Latifpour Z; Mardani E; Azarpira N; Asadi B; Najibi A
Biomed Pharmacother; 2017 Feb; 86():514-520. PubMed ID: 28024286
[TBL] [Abstract][Full Text] [Related]
35. Novel Insights Into Pathogenesis and Therapeutic Strategies of Hepatic Encephalopathy, From the Gut Microbiota Perspective.
Liu J; Xu Y; Jiang B
Front Cell Infect Microbiol; 2021; 11():586427. PubMed ID: 33692964
[TBL] [Abstract][Full Text] [Related]
36. Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood.
Dai X; Guo Z; Chen D; Li L; Song X; Liu T; Jin G; Li Y; Liu Y; Ajiguli A; Yang C; Wang B; Cao H
Gut Microbes; 2020 Jul; 11(4):1043-1063. PubMed ID: 32228300
[TBL] [Abstract][Full Text] [Related]
37. Engineering the gut microbiota to treat hyperammonemia.
Shen TC; Albenberg L; Bittinger K; Chehoud C; Chen YY; Judge CA; Chau L; Ni J; Sheng M; Lin A; Wilkins BJ; Buza EL; Lewis JD; Daikhin Y; Nissim I; Yudkoff M; Bushman FD; Wu GD
J Clin Invest; 2015 Jul; 125(7):2841-50. PubMed ID: 26098218
[TBL] [Abstract][Full Text] [Related]
38. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.
Campion D; Giovo I; Ponzo P; Saracco GM; Balzola F; Alessandria C
World J Hepatol; 2019 Jun; 11(6):489-512. PubMed ID: 31293718
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide in hepatic encephalopathy and hyperammonemia.
Rao VL
Neurochem Int; 2002; 41(2-3):161-70. PubMed ID: 12020616
[TBL] [Abstract][Full Text] [Related]
40. Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation?
Kronsten VT; Shawcross DL
Anal Biochem; 2022 Jan; 636():114437. PubMed ID: 34715068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
